T1	Participants 87 111	Guillian-Barre syndrome.
T2	Participants 183 276	plasma exchange (PE) and intravenous immunoglobulin (IVIg) for Guillian-Barre Syndrome (GBS).
T3	Participants 294 380	64 adult patients with GBS for PE and IVIg treatment, respectively, and nerve function
T4	Participants 852 876	reduce the GBS patients'
T5	Participants 1316 1342	rehabilitation of patients
